Brokerages Set Upstream Bio, Inc. (NASDAQ:UPB) Target Price at $56.50

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have been given an average rating of “Moderate Buy” by the five brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $56.50.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Upstream Bio in a report on Saturday, September 27th.

Upstream Bio Trading Down 1.6%

NASDAQ:UPB opened at $18.67 on Friday. Upstream Bio has a one year low of $5.14 and a one year high of $29.46. The firm’s fifty day moving average price is $17.42 and its two-hundred day moving average price is $12.30.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.13). Upstream Bio had a negative net margin of 3,836.58% and a negative return on equity of 35.90%. The company had revenue of $0.94 million during the quarter, compared to analyst estimates of $0.32 million. On average, sell-side analysts forecast that Upstream Bio will post -4.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Upstream Bio

A number of institutional investors have recently modified their holdings of the business. Invesco Ltd. boosted its position in shares of Upstream Bio by 6.4% in the second quarter. Invesco Ltd. now owns 16,300 shares of the company’s stock valued at $179,000 after acquiring an additional 985 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Upstream Bio by 8.4% in the second quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock valued at $181,000 after acquiring an additional 1,275 shares during the period. Legal & General Group Plc boosted its position in shares of Upstream Bio by 83.0% in the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after acquiring an additional 1,440 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Upstream Bio in the fourth quarter valued at about $25,000. Finally, CWM LLC boosted its position in shares of Upstream Bio by 107.5% in the second quarter. CWM LLC now owns 3,312 shares of the company’s stock valued at $36,000 after acquiring an additional 1,716 shares during the period.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.